Fig. 6.
RanBP6 suppresses growth factor output and glioma growth. a Focal deletions of the RANBP6 (left) and CDKN2A (right) loci in GBM. b Relationship between RANBP6 copy number and mRNA levels in GBM (n = 151); Tukey’s honest significant difference: ***p < 0.001. c RanBP6 protein levels in a panel of established patient-derived GBM tumor spheres. The immunoblots of whole-cell lysates are shown. d Ectopic expression of RanBP6-V5 in RanBP6-low TS516 GBM neurosphere reduces anchorage-independent growth. e Ectopic expression of RanBP6-V5 reduces EGFR protein levels in a time-dependent manner. f RanBP6 overexpression reduces tumor growth (left panel) and EGFR expression in a TS516 xenograft model (right panel). Student’s t test: *p < 0.05. g RanBP6 KD reduces survival in RCAS-tva mouse glioma model. Kaplan–Meier survival curves of PDGFB-induced gliomas generated in Nestin-tva mice injected with either RCAS-RanBP6 shRNA or RCAS-Luciferase shRNA as a control. h Tumor grade (WHO classification) of gliomas in the RCAS-tva model. i RanBP6 KD increases Egfr mRNA in samples from the RCAS-tva mice. Data in bar graphs are represented as mean ± SD (n ≥ 3)